Background: The aim of this study was to evaluate hospital readmission rates and
bAVR has had simultaneous increase in growth, with the thought that a valve-in-valve (V-I-V) TAVR could be performed when structural valve degeneration (SVD) of the bAVR occurs. 5 While bAVR is an attractive option in the short term, SVD is inevitable, particularly after the first decade of implantation. [6] [7] [8] [9] Mechanical AVR (mAVR) has the distinct advantage of long-term durability; however, postoperative bleeding events and readmission for bleeding have long been considered the principal disadvantage of mAVR. [10] [11] [12] [13] [14] However, this is not a universal finding and prior studies of bleeding events have demonstrated conflicting results. 15, 16 The objective of this study was to review our midterm outcomes of mAVR versus bAVR, with a particular focus on comparing hospital readmission rates and readmissions for bleeding.
| PATIENTS AND METHODS

| Study population
This study included all patients aged 50 years or older undergoing AVR at 
| Data analysis
Primary stratification was bAVR versus mAVR. 3 | RESULTS
| Baseline characteristics
The study population consisted of 2981 patients, predominantly composed of males (63%) who either underwent bAVR (n = 2575; 86%)
or mAVR (n = 406; 14%) ( Table 1 ). Patients undergoing bAVR were more likely to be older (73 ± 8 vs 61 ± 6 years; P < 0.001), have a higher
Society of Thoracic Surgeons predicted risk of operative mortality (4% ± 5% vs 3% ± 3%; P < 0.001), less likely to have severe aortic regurgitation (13% vs 24%; P < 0.001), and more likely to have severe tricuspid regurgitation (TR; 4% vs 3%; P < 0.001). The intraoperative variables are described in Table 2 . The majority of patients underwent a full sternotomy for both mAVR and bAVR. Patients undergoing mAVR were more likely to have had prior cardiac surgery (20% vs 14%; P < 0.001), more likely to have concomitant mitral valve surgery (18% vs 13%; P < 0.004), and less likely to have a concomitant coronary artery bypass graft (CABG; 30% vs 41%; P < 0.001). Patients 
| Operative mortality and morbidity
Postoperative outcomes are illustrated in 
| Unadjusted longitudinal outcomes
The mean follow-up was 2.9 ± 1.9 years. The unadjusted 1-year mortality was greater in patients undergoing bAVR versus mAVR (9.7% vs 6.3%; P = 0.039). This mortality trend continued at 5 years (27.6% vs 17.2%; P = 0.005) (Figure 2 ). There was no significant difference in freedom from hospital readmission between bAVR versus mAVR at 30 days (14.2% vs 15.2%; P = 0.427), 1 year (29.6% vs 27.2%; P = 0.427), and 5 years (54.8% vs 53.1%; P = 0.828) (Figure 3 ). Freedom from readmission for bleeding were similar between bAVR versus mAVR at 30 days (0.7% vs 1.0%; P = 0.614), 1 year (2.8% vs 3.0%; P = 0.789), and at 5 years (7.8% vs 9.5%; P = 0.355) (Figure 4 ). Only 31.8% of the readmissions in the bAVR cohort were cardiac in nature compared to 33.3% in the mAVR cohort (P = 0.423) ( Table 3) . Heart failure admissions were the leading cause of cardiac readmissions in both cohorts (13.5% in bAVR vs 16.1% in mAVR). Infectious etiology (22.2%) was the most common noncardiac etiology for bAVR, whereas malignancy (14.8%) was the most common etiology for noncardiac readmission in the mAVR group. One hundred percent of bleeding readmissions in the bAVR cohort versus 90.9% readmissions in the mAVR cohort were non-surgical in nature ( Table 4 ). The only bleeding Prior open-heart surgery, arrhythmia, congestive heart failure, cardiogenic shock, total bilirubin, systolic pulmonary artery pressure, ejection fraction, concomitant mitral valve disease, concomitant tricuspid valve disease, preoperative intra-aortic balloon pump, concomitant mitral valve procedure, concomitant tricuspid valve procedure. 1-year mortality: Mechanical versus bioprosthesis, diabetes, alcohol use, liver disease, pneumonia, dialysis, CVA, TIA. Malignancy in last 5 years, prior openheart surgery, arrhythmia, congestive heart failure, cardiogenic shock, creatinine, total bilirubin, ejection fraction, concomitant mitral valve disease, concomitant tricuspid valve disease, preoperative intra-aortic balloon pump, concomitant mitral valve procedure, concomitant tricuspid valve procedure, concomitant other major cardiac procedure. CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; CVD, cerebrovascular disease; HDEF, hemodynamic ejection fraction; HR, hazard ratio; IE, infective endocarditis; IV, intravenous; NYHA, New York Heart Association; PAD, peripheral artery disease; PASYS, pulmonary artery systolic pressure; TIA, transient ischemic attack The significant univariate variables that were used in the multivariate analysis that were not significant are indicated below. 30-day mortality: Mechanical versus bioprosthesis, diabetes, chronic lung disease (mild, severe), liver disease, dialysis, IE, immunosuppressive therapy, history of PAD and TIA. Carotid stenosis, arrhythmia, congestive heart failure, total albumin, PASYS. Concomitant CABG procedure, concomitant mitral procedure, concomitant tricuspid procedure. 1-year mortality: Mechanical versus bioprosthesis, sex, diabetes, chronic lung disease (mild), alcohol use, liver disease, sleep apnea, pneumonia, recent IV drug use, dialysis, IE, history of CVD, CVA, and TIA. Carotid stenosis, arrhythmia, congestive heart failure, PASYS, HDEF, concomitant CABG procedure, concomitant ventricular assist device placement, concomitant mitral procedure, concomitant tricuspid procedure. 5-year mortality: Mechanical versus bioprosthesis, age, sex, diabetes, alcohol use, liver disease, sleep apnea, pneumonia, recent IV drug use, dialysis, history of mediastinum radiation therapy, CVD, CVA, and TIA. Arrhythmia, congestive heart failure, creatinine, PASYS, HDEF, concomitant mitral procedure, concomitant tricuspid procedure. readmission that required surgical intervention was in an mAVR patient who underwent a splenectomy after a splenic injury presenting with hemoperitoneum.
| Risk-adjusted multivariable Cox regression models
The choice of prosthesis did not have a risk-adjusted impact on operative mortality at 30 days, 1 year, or 5 years (Table 5 The variables that significantly impacted hospital readmission at 30 days in the multivariable model included moderate COPD and heart failure symptoms (New York Heart Association classes I, III, and IV).
Multivariable predictors of 1-year readmission included mild, moderate, and severe COPD; immunosuppression; history of peripheral arterial disease; preoperative cardiogenic shock; lower serum albumin;
and the presence of MR (Table 6 ). In the model for 5-year readmission, independent predictors included older age, COPD, immunosuppression, peripheral arterial disease, preoperative cardiogenic shock, lower serum albumin, mitral stenosis, and concomitant CABG. Choice of prosthesis had no significant impact on 30-day, 1-year, or 5-year readmission in the multivariable models.
| DISCUSSION
The choice of prosthesis in the aortic position can be challenging despite several societal guidelines and considerable literature on the topic. Both patient-and prosthesis-related factors should be taken into account prior to the recommendation of a valve choice by the surgeon. mAVR in the aortic position remain an excellent treatment option in adolescents and young adults with freedom from valve-related events as high as 88% at 4 years. 17 Both mAVR and bAVR have risks and benefits with bleeding events generally occurring more frequently with mAVR and SVD more prevalent for bAVR. [10] [11] [12] [13] [14] However, the finding of increased bleeding events for mAVR is not consistent with recent studies. In 2013, the Society of Thoracic Surgeons Adult Cardiac Surgery National Database reported that there was a 20% increase in the proportion of patients selecting bAVR over mAVR among all age groups and this trend has continued. 24 The use of bAVR has continued to increase with the thought that when SVD occurs in bAVR, they can be treated with a TAVR V-I-V approach.
Unfortunately, despite good immediate procedural outcomes, V-I-V continues to have increased prosthetic valve mean gradients and greater risk for coronary obstruction. The ACC/AHA guidelienes that were updated in 2017 lowered the age threshold for the use of bAVR to patients over the age of 50 from 60 years of age. 4 However, the European guidelines continued to maintain the age limit of 60. 20 Our philosophy has been more in line with the latter as long as the patients life expectancy is likely to be more than 10 years. [27] [28] [29] [30] [31] Our results clearly indicate that with a careful multidisciplinary care team, close follow-up, and a compliant patient population, mAVR can have a bleeding risk that is similar to a bAVR without the increased risk of SVD.
| LIMITATIONS
This study has some of the limitations inherent to a retrospective study design. In addition, there is the possibility that there were some readmissions to outside facilities that were not captured in this analysis, although an advantage of our health system is that the vast majority of our patients are readmitted within one of our more than 30 hospitals in the region. Due to the extent of the study period, we were also unable to capture outcomes beyond 5 years. Moreover, we do not know whether patients with bAVR had a prior history of bleeding which would have affected the valve choice. We were unable to include all variables that may impact outcomes, such as compliance with anticoagulation or supratherapeutic anticoagulation, and therefore there exists the possibility of confounding by unmeasured variables. Finally, our results may be unique to our patient population and may not be similar to other cardiac centers. A multicenter study with a larger cohort of mAVR patients is necessary to define the incidence of readmissions and bleeding episodes between mAVR and bAVR.
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